Associated Papers
[Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate].
Steenbock O et al.
Urologie (heidelberg, Germany), 2025
Decoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription.
Altıntaş UB et al.
Nature Communications, 2024
39489778 (PubMed )
Supplement: 41467_2024_53758_MOESM2_ESM.pdf
Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES et al.
Jco Precision Oncology, 2024
Constructing and interpreting a large-scale variant effect map for an ultrarare disease gene: Comprehensive prediction of the functional impact of PSAT1 genotypes.
Xie MJ et al.
Plos Genetics, 2023
37812589 (PubMed )
Supplement: pgen.1010972.s017.xlsx › Table_S3
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N et al.
Genome Biology, 2016
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen EJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Select a paper to view details